New Treatment Arrests Progression of Type 1 Diabetes in Newly Diagnosed Patients
In the May 30, 2002 issue of The New England Journal of Medicine, researchers Dr. Kevan Herold of Columbia University and Dr. Jeffrey Bluestone of the University of California at San Francisco reported on the effectiveness of a new drug therapy designed to stop the progression of type 1 diabetes in newly diagnosed patients. The drug, a monoclonal antibody called hOKT3gamma1(Ala-Ala), was used in a preliminary study and appears to offer the hope for an effective treatment for type 1 diabetes once diagnosed.
In the preliminary study, 24 patients who were within six weeks of diagnosis were randomly split into two groups. The 12 patients in the treatment group received the new drug, while the 12 patients in the control group did not. Nine of 12 patients in the treatment group experienced improved or equal insulin response over one year after just two weeks of treatment. Ten of the 12 control patients experienced the typical decline in insulin production. Furthermore, patients in the treatment group required significantly less insulin and had significantly lower HbA1c levels than patients in the control group. "After one year, the average insulin dose in the monoclonal-antibody group was below the level that is considered to indicate clinical remission (0.5 U per kilogram per day)," the researchers report.
Dr. Jeffrey Bluestone
Dr. Kevan Herold
How To Participate
Anyone interested in participating in future studies can contact Dr. Kevan Herold, the principal investigator, at the Naomi Berrie Diabetes Center at Columbia-Presbyterian in New York at (212) 305-5025.
Insights From the Researchers
We asked Dr. Kevan Herold, principal investigator, and Dr. Jeffrey Bluestone, one of the authors and inventor of the monoclonal antibody used in the study, for their comments on this exciting study.
From Dr. Herold
Of importance for patients with diabetes is that, unlike other immune suppressive agents tried in diabetes, this agent appears to work for a long period of time without the need for continuous administration, and continuous immune suppression. This clearly reduces the potential complications compared to the previously tried approaches.
We are also interested in determining whether the drug needs to be given within the first 6 weeks after diagnosis or whether it may also be effective beyond that point. We have proposed a trial for patients who have had diabetes for 2 - 6 months. Of course, the obvious question that arises is if islet cells are continuously produced in patients with diabetes but eliminated by the immune response as soon as they develop, what would happen if one was able to arrest the immune response. We don't have information on this at this time but will be very interested in answering it in the future.
From Dr. Bluestone
- Question #1. What is the implication of this work for people developing Type 1 diabetes?
- I believe that the major finding is that we can intervene early after disease onset to prevent further insulin-producing islet cell destruction. Beyond the fact that it seems to work well, the study has broad implications for supporting the use of other novel immunotherapies in new onset diabetes. It is my hope that we will eventually be able to cause permanent remission at this early stage of the disease
- Question #2. Where do you go from here?
- Obviously, although these results clearly show that we can slow down or even prevent progression of the disease in patients where we intervene early, a real cure will depend on either identifying these patients in the prediabetic state (before clinical disease) or replacing the insulin-producing cells through islet or stem cell transplantation. We are getting much better at predicting those patients at high risk and I hope that therapies such as the hOKT3g1 (Ala-Ala) will be tested in these individuals, to see if we can stop the disease before it causes clinical problems. As far as islet transplantation is concerned, we have already met with some success using this anti-CD3 monoclonal antibody in a small pilot study and are actively pursuing new clinical trials at both UCSF and University of Minnesota.
- Question #3. Are there any potential uses of this drug beyond the setting of new onset diabetes
- Given that the drug appears to selectively attack only disease-producing autoimmune cells, it is logical that this antibody would have many other applications in autoimmune diseases, as well as organ and bone marrow transplantation. We are currently testing the drug in psoriatic arthritis in an Immune Tolerance Network-sponsored phase II trial. It is also being tested for use in islet transplantation. In the future we hope to examine its usefulness in other disease settings.
- Question #4. How does the drug work?
- The anti-CD3 mAb acts on the T cells of the immune system - these include the cells responsible for the destruction of insulin production. The drug stimulates the production of protective immune signaling molecules to reorient the immune response from a destructive to a protective one. The antibody appears to selectively inhibit previously activated immune T cells involved in the disease process. So in effect, we're reprogramming the immune cells that, in diabetics, destroy the insulin-producing islet cells.
- Question #5. Are there any concerns?
- Anytime you treat someone with an immunosuppressive agent there are concerns about increased infections or other side effects. However, one of the strengths of this therapy is that right now, it is given over a short (2 week) period of time, limiting the long term side effects seen with other immunosuppressants. However, one of our major goals is to continue to develop therapies that are as specific as possible, targeting only the disease causing T cells while leaving the normal, disease-fighting part of the immune system to continue it's work.
For More Information
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus from The New England Journal of Medicine
- PubMed Abstract
- Short-Term Use of New Drug Safely Arrests Type 1 Diabetes for One Year
- Drug Shows Great Promise Against Juvenile Diabetes (Free registration at The New York Times web site required)
- Immune Tolerance Network To Begin Multicenter Clinical Trial Of Diabetes-delaying Therapy
- Type 1 Diabetes Safely Arrested with Short-Term Use of New Drug from the University of California at San Francisco
- Joint Columbia / UCSF Press Release
- Search For A Cure
31 May 2002
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.